Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2024 Results Conference Call October 30, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brenton Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Xuyang Li - Jefferies Matt Miksic - Barclays Doug Miehm - RBC Capital Markets Lilia-Celine Lozada - JPMorgan Operator Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
- 10/30/2024
|
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 10/30/2024
|
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates
- Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago.
- 10/30/2024
|
Why Bausch + Lomb Stock Soared by Over 7% on Monday
- It was quite a busy and eventful day for the company.
- 10/14/2024
|
Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid
- Bausch + Lomb Corporation (BLCO) shares popped Monday morning following reports Blackstone (BX) and TPG (TPG) are considering teaming up to buy the eyecare company.
- 10/14/2024
|
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
- This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors.
- 09/22/2024
|
Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?
- Bausch + Lomb (BLCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 09/17/2024
|
Why Bausch + Lomb Rallied Today
- The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal.
- 09/16/2024
|
Bausch + Lomb Stock Jumps Amid Reports Of A Sale
- Bausch + Lomb (BLCO) shares popped Monday following a report that the eyecare company is considering a sale.
- 09/16/2024
|
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
- Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.
- 09/16/2024
|
Bausch & Lomb reportedly exploring sale, shares rise
- Bausch & Lomb stock surged on reports the American-Canadian eye health products firm is exploring a sale as it seeks to resolve issues related to its separation from its debt-laden parent company Bausch Health Cos Inc (NYSE:BHC). According to a Financial Times report citing people familiar with the matter, Bausch & Lomb is working with Goldman Sachs to gauge interest from potential buyers.
- 09/16/2024
|
Bausch + Lomb Corporation (BLCO) Q2 2024 Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2024 Earnings Call July 31, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Robbie Marcus - JPMorgan Douglas Miehm - RBC Capital Markets Matt Miksic - Barclays Operator Good morning, and welcome to Bausch + Lomb's Second Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
- 07/31/2024
|
Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 07/31/2024
|
Bausch + Lomb (BLCO) Matches Q2 Earnings Estimates
- Bausch + Lomb (BLCO) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.18 per share a year ago.
- 07/31/2024
|
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
- Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/24/2024
|
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from.
- 06/17/2024
|
Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company's proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day co.
- 06/10/2024
|
Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as little as two to four weeks.1,2* “We offer dry eye sufferers a wide array of options tha.
- 06/03/2024
|
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Nathalie Bernier 344,550,519 28.
- 05/29/2024
|
Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. “enVista Envy is the next step in the dram.
- 05/28/2024
|
Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants George Gadkowski - VP, IR & Business Insights Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Robbie Marcus - JPMorgan Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Matt Miksic - Barclays Doug Miehm - RBC Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
- 05/01/2024
|
Bausch + Lomb Announces First-Quarter 2024 Results
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. “Outperformance from each of our business units and solid results across geographies led to an impressive quarter and once again demonstrated our quality of growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our key franchises continue to deliver, and a focu.
- 05/01/2024
|
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the compa.
- 04/29/2024
|
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published statistically significant results from a clinical study evaluating the efficacy and safety of a novel daily nutritional supplement formulated to address the symptoms of dry eyes.1 Bausch + Lomb expects to launch the supplement, which features a proprietary blend of ingredient.
- 04/25/2024
|
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
- Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/24/2024
|
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue® Eye Care Recycling programs have collected 84,343,540 units, or 510,116 pounds, of used contact lenses, eye care and lens care materials in the U.S., which is greater than the weight of the Statue of Liberty.1 “Eye care professionals, patients and consumers have helped us collect hund.
- 04/18/2024
|
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
- VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of.
- 04/15/2024
|
BLCO vs. AVTR: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?
- 04/08/2024
|
All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy
- Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/25/2024
|
BLCO or AVTR: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?
- 03/21/2024
|
BLCO or AVTR: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or Avantor, Inc. (AVTR). But which of these two stocks presents investors with the better value opportunity right now?
- 03/21/2024
|
Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock
- Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 03/20/2024
|
Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
- Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
- 02/21/2024
|
Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/21/2024
|
Bausch & Lomb's stock soars 11% after earnings beat
- Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.
- 02/21/2024
|
Seeking Clues to Bausch + Lomb (BLCO) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Bausch + Lomb (BLCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
- 02/15/2024
|
Will Bausch + Lomb (BLCO) Beat Estimates Again in Its Next Earnings Report?
- Bausch + Lomb (BLCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 02/14/2024
|
Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Should You Buy?
- Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/14/2024
|
Alcon's stock falls as third-quarter sales miss estimates
- Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.
- 11/15/2023
|
Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Young Li - Jefferies Craig Bijou - Bank of America Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Douglas Miehm - RBC Capital Markets Operator Good morning and welcome to the Bausch + Lomb Third Quarter 2023 Earnings Call. All participants will be in a listen-only mode.
- 11/01/2023
|
Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?
- Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.
- 09/19/2023
|
Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates
- Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.29 per share a year ago.
- 08/02/2023
|
BLCO or DOCS: Which Is the Better Value Stock Right Now?
- Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and Doximity (DOCS). But which of these two stocks is more attractive to value investors?
- 07/06/2023
|
Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates
- Bausch + Lomb (BLCO) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.24 per share a year ago.
- 05/03/2023
|
Bausch + Lomb: Brent Saunders Return Bodes Well For Shareholders
- Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie.
- 02/27/2023
|
Bausch + Lomb Corporation (BLCO) Q4 2022 Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Art Shannon – Investor Relations Joe Papa – Chief Executive Officer Brent Saunders – Incoming Chief Executive Officer and Chairman of the Board of Directors Sam Eldessouky – Executive Vice President and Chief Financial Officer Conference Call Participants Craig Bijou – Bank of America Cecilia Furlong – Morgan Stanley Matt Miksic – Barclays Vijay Kumar – Evercore ISI Joanne Wuensch – Citi Operator Good morning, and welcome to Bausch + Lomb's Fourth Quarter 2022 Earnings Call. All participants will be in a listen-only mode.
- 02/22/2023
|
Bausch + Lomb beats Q4 profit and revenue estimates
- Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings of $51 million, or 15 cents a share, in the year-earlier period. The company, which went public in May when it was spun out of Bausch Health, said adjusted per-share earnings came to 23 cents, a penny ahead of the 22 cent FactSet consensus.
- 02/22/2023
|
After IPO, Bausch + Lomb turns to an industry favorite to run the company
- Bausch + Lomb Corp.'s decision to bring back Brent Saunders as CEO hints at the company's broader ambitions in the global eye-care market.
- 02/15/2023
|
Bausch + Lomb names ex-CEO Brent Saunders as CEO, replacing Joseph Papa
- Bausch + Lomb Corp. BLCO, +1.31% said Wednesday it has named Brent Saunders as chief executive and chair effective March 6. Saunders, who will return to the company he headed from 2010 to 2013, will replace Joseph Papa, who is stepping down.
- 02/15/2023
|
Bausch + Lomb: A Solid Play In Challenging Economic Times
- Over the long term, its geographic mix of over 100 countries is a strength, but near term, the strength of the U.S. dollar is weighing on its performance. Strong brands and pricing power support the company under the weak economic environment.
- 11/09/2022
|
Bausch + Lomb Corporation (BLCO) Q3 2022 Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Alison Ryan - Investor Relations Joseph Papa - Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Zack Weiner - Jefferies Cecilia Furlong - Morgan Stanley Vijay Kumar - Evercore Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Operator Good morning, and welcome to the Bausch + Lomb Third Quarter 2022 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
- 11/06/2022
|
Bausch + Lomb beats earnings expectations in Q3
- Bausch & Lomb Corp. BLCO, +0.63% said Wednesday that it had a loss of $18 million, or 5 cents per share, in the first quarter of 2022, after a gain of $60 million, or 17 cents per share, in the same quarter a year ago. Adjusted earnings per share were 31 cents, against a FactSet consensus of 23 cents.
- 11/02/2022
|
Recent Investments By Top Activist Investors Include Bausch + Lomb, Twitter, BBBY & GameStop - Buyers Beware
- Activist investors purchase a majority of publicly traded shares in companies they believe need to be improved. It doesn't always work out for the company or its shareholders, so let's examine what investors need to know about these stocks.
- 09/15/2022
|
Bausch + Lomb: Strong Buy After IPO Lock-Up Date
- Bausch + Lomb offers a variety of lenses that provide a competitive advantage for every type of consumer. The long-term outlook looks bright due to the strong catalysts, but the short-term outlook is mixed due to the IPO lock-up date.
- 08/25/2022
|
Bausch + Lomb: Traders Eye A Key IPO Lockup Date On This Rangebound Stock
- The U.S. IPO market is ice cold following a hot 2021. One May IPO, Bausch + Lomb, is a household name with high uncertainty regarding a planned spinoff and a key drug.
- 08/23/2022
|
BLCO vs. DOCS: Which Stock Should Value Investors Buy Now?
- BLCO vs. DOCS: Which Stock Is the Better Value Option?
- 08/09/2022
|
Bausch + Lomb Corporation (BLCO) CEO Joseph Papa on Q2 2022 Results - Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Arthur Shannon - Investor Relations Joseph Papa - Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi Craig Bijou - Bank of America Imron Zafar - Deutsche Bank Doug Miehm - RBC Capital Markets Yatin Suneja - Guggenheim Partners Cecilia Furlong - Morgan Stanley Vijay Kumar - Evercore Zack Weiner - Jefferies Operator Good morning, and welcome to the Bausch + Lomb's Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode.
- 08/07/2022
|
Bausch + Lomb beats earnings and revenue expectations; stock is up 3%
- Shares of Bausch + Lomb Corp. BLCO, +4.15% were up 3.1% in premarket trading on Thursday after the eyecare company outperformed earnings and revenue expectations in the second quarter of 2022. Bausch had earnings of $5 million, or 1 cent per share, in the second quarter of the year, down from $44 million, or 13 cents per share, in the same quarter a year ago.
- 08/04/2022
|
Investors May Want to Follow Progress of VC-Backed Medtechs
- At least one group is bullish about the outlook for the medtech industry: venture capitalists.
- 07/25/2022
|
Bausch Health Companies: 2022's Most Compelling Special Situation
- BHC's stake in BLCO that is set to be distributed to shareholders is worth more than the current market capitalization of the entirety of BHC, giving investors a compelling return. The BLCO spinoff and Solta Medical IPO proceeds are sufficient for BHC to shoulder its approximately $20 billion debt load.
- 06/10/2022
|
Bausch + Lomb: Shares Deserve Some Upside
- Recent financial performance reported by Bausch + Lomb has been encouraging from a sales perspective. However, the company's bottom line is facing continued difficulties.
- 06/09/2022
|
Bausch + Lomb Corporation (BLCO) CEO Joe Papa on Q1 2022 Results - Earnings Call Transcript
- Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2022 Results Conference Call June 8, 2022 8:00 AM ET Company Participants Allison Ryan - Director, IR Joe Papa - Chairman, CEO Sam Eldessouky - CFO Conference Call Participants Cecilia Furlong - Morgan Stanley Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Robbie Marcus - JP Morgan Yatin Suneja - Guggenheim Partners Joanne Wuensch - Citi Zach Weiner - Jefferies Ken Cacciatore - Cowen Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2022 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
- 06/08/2022
|
Bausch + Lomb tops profit expectations but revenue comes up shy
- Bausch + Lomb Corp. BLCO, -3.16% reported Wednesday first-quarter profit that topped expectations but revenue that came up short, as growth in vision care and surgical segment revenue was partially offset by declines in ophthalmic pharmaceuticals revenue. The contact lens and surgical device maker's stock was still inactive in premarket trading.
- 06/08/2022
|
It's Time To Nibble On These Two Recent IPOs
- It's hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen (NASDAQ: PEPG) both IPOd in 2022 and have seen their shares plummet in the wake of the offering, not because they are poor companies or bad investments but simply because the market conditions changed.
- 05/31/2022
|
Bausch Health Companies: Headwinds, Again
- Bausch Health has seen a very tough 2022 as investors price in higher interest rates on its massive debt load and softer IPO of its subsidiary Bausch + Lomb. These are not encouraging trends, but the valuation reset has been enormous, potentially creating an opportunistic investment opportunity here.
- 05/10/2022
|
BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today
- Here's what investors in Bausch + Lomb may want to know about the highly anticipated BLCO stock IPO, which took place today. The post BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today appeared first on InvestorPlace.
- 05/06/2022
|
Bausch + Lomb valued at $6.5 billion after stock ticks up in NYSE debut
- (Reuters) -Bausch + Lomb was valued at $6.48 billion in its U.S. market debut on Friday as the eye-care company's shares opened nearly 3% above an offer price that was well below the targeted range.
- 05/06/2022
|
Bausch + Lomb stock opens with a slight gain, to value the company at about $6.5 billion
- Bausch + Lomb Corp.'s stock BLCO, +5.39% debuted Friday with a slight gain, which helped justify the disappointing pricing overnight of the lenses and medical devices maker's initial public offering. The company said late Thursday that its IPO priced at $18 a share, which was well below the expected range of between $21 and $24, as the company raised $630 million.
- 05/06/2022
|
Busted Bausch + Lomb IPO To Doom IPO Market, Cash Burning Startups
- Bausch + Lomb's busted IPO will cost its parent billions in write-downs. It also signals trouble ahead for the IPO market and venture backed startups
- 05/06/2022
|
Bausch + Lomb prices IPO at $18 a share, below expectations
- Bausch + Lomb Corp. priced its IPO at $18 a share Thursday, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market.
- 05/06/2022
|
Bausch + Lomb's IPO Will Likely be Priced Below Expectations
- In a move that highlights the constraints of the current market, eye care company Bausch + Lomb will likely price its initial public offering (IPO) at the low end of expectations, The Wall Street Journal wrote Thursday (May 5). The report said bankers involved in the deal have told investors that the stock will be […]
- 05/05/2022
|
Bausch + Lomb IPO: What You Need to Know
- Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market. Bausch Health Companies (BHC) is a global healthcare stock that develops pharmaceuticals, medical devices and over-the-counter medications, with focus areas in eye health, gastroenterology and dermatology.
- 05/03/2022
|
BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?
- Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week. The post BLCO Stock IPO: When Does Bausch + Lomb Go Public?
- 05/02/2022
|
IPO Report: U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb
- The U.S. initial public offering market is bracing for what is expected to be the second-biggest deal of the year so far this week, that of eyecare company Bausch & Lomb, which is expected to raise up to $840 million at a valuation of more than $8 billion.
- 05/02/2022
|
Bausch + Lomb Targets $788 Million IPO
- Bausch + Lomb has filed proposed terms for a $788 million IPO. The firm develops and sells contact lens and other eyecare products worldwide.
- 04/29/2022
|
U.S. IPO Weekly Recap: The Q122 IPO Market Closes Out With SPACs And Pipeline News
- The 1Q22 IPO market ended with another quiet week. Just two SPACs priced.
- 04/02/2022
|
